ArticleOphthalmology science2026
Automated Triage for New Keratoconus Referrals Using Multimodal Deep Learning.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop and validate deep learning models for predicting keratoconus progression risk using multimodal imaging and clinical data, enabling risk-stratified patient monitoring. Design: A retrospective cohort study with external validation. Participants: We analyzed 7396 eyes of 3893 patients (internal dataset) and 963 eyes of 519 patients (external validation dataset) with keratoconus who underwent MS-39 (CSO Italia) anterior-segment OCT (AS-OCT) and Placido topography between October 2020 and June 2024. Methods: Progression was defined using the global consensus criteria requiring changes in multiple parameters above device-specific precision limits. We compared conventional machine learning, unimodal deep learning, and multimodal fusion architectures to predict 2-year progression risk from baseline data. We developed recurrent neural networks to incorporate data from sequential clinic visits. We assessed clinical utility through simulated risk-stratified triage pathways in an external validation cohort. Main Outcome Measures: The area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, and predictive values for keratoconus progression within 2 years were measured. Results: The multimodal model of AS-OCT, Placido, and tabular data yielded the best single-visit prediction (AUROC 0.84, 95% confidence interval [CI]: 0.83-0.85); adding sequential visits via long short-term memory boosted this to 0.93 (95% CI: 0.91-0.96). Fifty-eight percent of patients could be classified as low risk (90% chance of correctly predicting no progression in 2 years) after their baseline clinic visit, rising to 83% with inclusion of data from a second clinic visit. Conclusions: Artificial intelligence models can be used to develop risk-stratified pathways for monitoring keratoconus, reducing unnecessary follow-up for patients at low risk of progression while ensuring optimal resource allocation and timely intervention for those at high risk. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.